Evidence map›Paper›PMID 38509849›Full record

ArticleESC heart failure2024

Analysis of the serum levels of RIP3 and Drp1 in patients with heart failure.

Izabela Jarabicová, Csaba Horváth, Martin Chudý, Eva Goncalvesová, Adriana Adameová

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Izabela JarabicováFaculty of Pharmacy, Department of Pharmacology and Toxicology, Comenius University, Bratislava, Slovak Republic.
Csaba HorváthFaculty of Pharmacy, Department of Pharmacology and Toxicology, Comenius University, Bratislava, Slovak Republic.
Martin ChudýFaculty of Medicine, Department of Cardiology, Comenius University and National Cardiovascular Institute, Bratislava, Slovak Republic.
Eva GoncalvesováFaculty of Medicine, Department of Cardiology, Comenius University and National Cardiovascular Institute, Bratislava, Slovak Republic.
Adriana AdameováFaculty of Pharmacy, Department of Pharmacology and Toxicology, Comenius University, Bratislava, Slovak Republic.

Funding

Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic VEGA 1/0016/20Slovak Research and Development Agency APVV-15-0607Slovak Research and Development Agency APVV-20-0242
6 · The paper itself

Abstract

aimsAs necroptosis involving receptor-interacting protein kinase 3 (RIP3) and dynamin-related protein 1 (Drp1)-mediated signalling is a crucial mechanism of cell loss in heart failure (HF), we aimed to determine the potential diagnostic use of these molecules. METHODS AND

resultsThe serum samples of the healthy subjects (n = 8) and patients with HF with reduced ejection fraction (n = 31), being subdivided according to the aetiology and New York Heart Association (NYHA) class, were used to measure RIP3 and Drp1 levels by enzyme-linked immunosorbent assay. Although the serum levels of Drp1 in the patients with HF were comparable with those seen in healthy individuals, we found a trend of increase in the levels of RIP3 (P = 0.0697) in the diseased group. These changes were unlikely dependent on the HF aetiology or NYHA class. The circulating RIP3 correlated with neither the main parameters assessing cardiac function (left ventricular ejection fraction, left ventricular end-diastolic diameter, and N-terminal pro-brain natriuretic peptide) nor the marker of inflammation (C-reactive protein).

conclusionsIn this pilot study, findings on serum RIP3 supported the importance of necroptosis in HF pathomechanisms. The potential diagnostic use of circulating RIP3, unlike Drp1, as an additional biomarker of HF has also been indicated; however, further large studies are needed to prove this concept.

Indexed as

BiomarkersDynaminsHeart FailureReceptor-Interacting Protein Serine-Threonine KinasesAgedEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedPilot ProjectsStroke VolumeVentricular Function, LeftBiomarkersDNM1L protein, humanDynaminsReceptor-Interacting Protein Serine-Threonine KinasesRIPK3 protein, humanDynamin‐related protein 1Heart failureNecroptosisReceptor‐interacting protein kinase 3

Identifiers

PMID38509849
PMCPMC11287288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.